Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
Journal of Thrombosis and Haemostasis (JTH) has shared a post on LinkedIn:
“Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of the BENEFIT trial
In this phase 3 trial of 257 patients with transplant-ineligible newly diagnosed multiple myeloma, the 6-month cumulative incidence of VTE was 4.8%. Among prophylaxis strategies, low-dose DOACs significantly reduced VTE risk compared to heparin or aspirin. Proteinuria ≥0.44 g/L and monoclonal protein ≥22 g/L emerged as strong independent risk factors for VTE. Findings highlight DOACs as a potentially superior prophylaxis option in this high-risk population.”
Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Authors: Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet–Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu
Read the full paper here.
Find similar posts on Hemostasis Today.
-
Apr 23, 2026, 16:26Ifeanyichukwu Ifechidere: The Framework for Mastering Coagulation Fundamentals
-
Apr 23, 2026, 16:12Fayad Al-Haimus։ HI-PEITHO Shows Reduced PE Complications Without Increased Bleeding
-
Apr 23, 2026, 16:04Hamid Yousaif Qureshi: Japanese Scientists Develop Artificial Blood
-
Apr 23, 2026, 15:5810 Treating Fairly Research Awards – ASH
-
Apr 23, 2026, 15:51Abeer Alanazi: Secondary Stroke Prevention in Atrial Fibrillation
-
Apr 23, 2026, 15:46Brian O Mahony: What Causes the Battle Bettle Between AAV and the Liver?
-
Apr 23, 2026, 15:45Toong Youttananukorn: Excited to Share Our Poster at WFH 2026
-
Apr 23, 2026, 15:42Flora Peyvandi: Management of Antithrombotic Treatment in Atrial Fibrillation
-
Apr 23, 2026, 15:38William Aird: Do We Really Need MCH?